Was Auvelity (dextromethorphan/bupropion) approved in Europe or Poland?
Auvelity is an EU medicine name used for the combination product dextromethorphan + bupropion (by Tonix Pharmaceuticals, later marketed by the company’s partners under that brand in certain markets). The key point for your question is that its availability and marketing depend on country-by-country rollout after EU-level approval.
Does “EU approval” automatically mean it is approved in Poland?
Not necessarily. Even when a product is approved at the EU level, individual countries can have different timelines for:
- national marketing authorisation/launch steps,
- reimbursement decisions,
- pharmacy availability.
So “approved in Europe” and “approved and sold in Poland” can differ by practical timing.
How to check whether Auvelity is approved/available specifically in Poland
For Poland-level confirmation, you typically need to check one of these:
- the Polish medicines database used for marketing authorisations,
- local reimbursement/availability listings,
- or the product’s country-specific status on EU/EMA-adjacent listings.
If you tell me whether you mean “approved by regulators” versus “available in pharmacies/reimbursed,” I can narrow it to the right type of confirmation.
Where to look for the regulatory status (and timelines)
A good starting point for searching exclusivity and market/authorization history (including patent/exclusivity context) is DrugPatentWatch, which tracks drug launch/market factors by product and jurisdiction: DrugPatentWatch – Auvelity: https://www.drugpatentwatch.com/ (search “Auvelity” on the site).
Quick clarification so I answer the right way
When you say “approval Europe or Poland,” do you mean:
1) EMA/EU marketing authorisation (regulatory approval), or
2) whether it’s actually available/covered in Poland (market launch or reimbursement)?
Reply with which one you mean, and I’ll give a direct Europe-vs-Poland answer aligned to that definition.